|
Name |
Calbistrin H
|
Molecular Formula | C28H44O9 | |
IUPAC Name* |
[(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3-(hydroxymethyl)-7,8-dimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyldeca-4,6-dienoate
|
|
SMILES |
C[C@H]1C=C[C@H]2C[C@H](C[C@@H]([C@@H]2[C@@]1(C)C(=O)C(CO)O)OC(=O)[C@@H](C)[C@H](/C(=C/C=C/[C@@H]([C@@H](C)O)O)/C)O)CO
|
|
InChI |
InChI=1S/C28H44O9/c1-15(7-6-8-21(32)18(4)31)25(34)17(3)27(36)37-23-12-19(13-29)11-20-10-9-16(2)28(5,24(20)23)26(35)22(33)14-30/h6-10,16-25,29-34H,11-14H2,1-5H3/b8-6+,15-7+/t16-,17-,18+,19+,20-,21-,22?,23-,24+,25-,28-/m0/s1
|
|
InChIKey |
PWYIRLZQQKCIPQ-ROXQJYFVSA-N
|
|
Synonyms |
Calbistrin H; CHEMBL3358714; [(1S,3R,4aR,7S,8S,8aS)-8-(2,3-dihydroxypropanoyl)-3-(hydroxymethyl)-7,8-dimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyl-deca-4,6-dienoate
|
|
CAS | NA | |
PubChem CID | 118723028 | |
ChEMBL ID | CHEMBL3358714 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 524.6 | ALogp: | 1.1 |
HBD: | 6 | HBA: | 9 |
Rotatable Bonds: | 12 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 165.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 37 | QED Weighted: | 0.133 |
Caco-2 Permeability: | -5.301 | MDCK Permeability: | 0.00043201 |
Pgp-inhibitor: | 0.021 | Pgp-substrate: | 0.998 |
Human Intestinal Absorption (HIA): | 0.192 | 20% Bioavailability (F20%): | 0.02 |
30% Bioavailability (F30%): | 0.965 |
Blood-Brain-Barrier Penetration (BBB): | 0.14 | Plasma Protein Binding (PPB): | 30.59% |
Volume Distribution (VD): | 0.35 | Fu: | 21.70% |
CYP1A2-inhibitor: | 0.032 | CYP1A2-substrate: | 0.097 |
CYP2C19-inhibitor: | 0.009 | CYP2C19-substrate: | 0.644 |
CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.158 |
CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.071 |
CYP3A4-inhibitor: | 0.407 | CYP3A4-substrate: | 0.217 |
Clearance (CL): | 2.128 | Half-life (T1/2): | 0.83 |
hERG Blockers: | 0.067 | Human Hepatotoxicity (H-HT): | 0.821 |
Drug-inuced Liver Injury (DILI): | 0.803 | AMES Toxicity: | 0.03 |
Rat Oral Acute Toxicity: | 0.091 | Maximum Recommended Daily Dose: | 0.018 |
Skin Sensitization: | 0.095 | Carcinogencity: | 0.062 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.713 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003293 | 0.856 | D02RQU | 0.261 | ||||
ENC003292 | 0.721 | D0E9KA | 0.216 | ||||
ENC004660 | 0.331 | D06WTZ | 0.211 | ||||
ENC003665 | 0.324 | D02KFP | 0.206 | ||||
ENC003895 | 0.312 | D0X7XG | 0.194 | ||||
ENC003792 | 0.304 | D03JSJ | 0.190 | ||||
ENC004127 | 0.303 | D0Q0EX | 0.189 | ||||
ENC004128 | 0.295 | D0S0AS | 0.187 | ||||
ENC003166 | 0.260 | D06PTA | 0.187 | ||||
ENC005723 | 0.259 | D0G7KJ | 0.186 |